|
MINNEAPOLIS, MINNESOTA--(Marketwired - Dec. 1, 2016) - DiaMedica Inc. (the "Company") (TSX VENTURE:DMA)(OTCQB:DMCAF) today announced the sale and transfer of its DM-71 product and related intellectual property. The sale of this non-core asset provides DiaMedica with a total of $300,000 in upfront payments, of which $50,000 had been previously received, and a royalty stream linked to future sales. |
